All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @katgosik on TikTok · 62s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @katgosik's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00The internet has influenced me. I started my peptide journey and I want to talk to you guys because I am so curious what else I should be taking.
  2. 0:09I started on GHK-Cu about two weeks ago now and I've been on NAD. I know NAD is not a peptide but I've been on it for about three months and I take NAD mostly for mental brain function and not having that afternoon crash which it has really helped with.
  3. 0:28Usually when I'm working I get tired around 3pm. I'm like okay I'm ready for an app but this is helping me and then I haven't noticed really anything with the GHK-Cu yet.
  4. 0:41I think it takes about four weeks to really show in your skin and your hair but I wanted to see if you guys had any recommendations what else I should be taking.
  5. 0:52If you've taken it any tips, tricks and yeah any insight is greatly appreciated.

BPC-157 healing claims on TikTok: what the science shows

kathryn gosik 🫧🤍

TikTok creator

18.8K viewsWatch on TikTok

Quick answer

The creator is self-administering GHK-Cu (a copper-binding tripeptide with preclinical data on collagen synthesis) and NAD supplementation concurrently, primarily targeting skin appearance and cognitive energy. Neither compound has FDA approval for these indications, and the human evidence base for GHK-Cu specifically remains limited to small studies and preclinical models. Crowdsourcing additional peptide stacks from social media followers without medical supervision presents compounding safety and quality-control concerns.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksBPC-157Provider discussion

Evidence signal

Source-backed review

Regulatory reality

BPC-157 access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For BPC-157 healing claims on TikTok: what the science shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

BPC-157 is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this bpc-157 video claims cluster

Best for searchers trying to separate BPC-157 research signals from overconfident recovery claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "BPC-157 healing claims on TikTok: what the science shows" from kathryn gosik 🫧🤍. We read the clip as a Peptide social video fact-checks claim about BPC-157, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is self-administering GHK-Cu (a copper-binding tripeptide with preclinical data on collagen synthesis) and NAD supplementation concurrently, primarily targeting skin appearance and cognitive energy.

The reason this review is not generic is the source wording and the canonical claim label "peptides tiktok 7614996068073245983." In this clip, the useful excerpt is: "The internet has influenced me." That wording changes the review because it points to BPC-157 safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Multifunctionality and Possible Medical Application of the BPC 157 Peptide (2025), Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing (2019), and Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (2025), plus the creator's own wording. BPC-157 still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

NAD precursor supplementation has been shown to raise blood NAD levels in humans (Yoshino et al.
People who land here are usually trying to understand whether the BPC-157 claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' BPC-157 guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator is self-administering GHK-Cu (a copper-binding tripeptide with preclinical data on collagen synthesis) and NAD supplementation concurrently, primarily targeting skin appearance and cognitive energy.

FormBlends verdict

BPC-157 safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the BPC-157 guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is self-administering GHK-Cu (a copper-binding tripeptide with preclinical data on collagen synthesis) and NAD supplementation concurrently, primarily targeting skin appearance and cognitive energy. Neither compound has FDA approval for these indications, and the human evidence base for GHK-Cu specifically remains limited to small studies and preclinical models. Crowdsourcing additional peptide stacks from social media followers without medical supervision presents compounding safety and quality-control concerns.
  • GHK-Cu human trial data is sparse; most evidence comes from cell culture and animal studies, with no large RCTs confirming skin or hair benefits at any specific timeline.
  • NAD precursor supplementation has been shown to raise blood NAD levels in humans (Yoshino et al., 2021, Science), but cognitive and fatigue endpoints like 'afternoon crash' have not been rigorously tested in clinical settings.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • BPC-157 decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the BPC-157 guide, cost path, safety notes, and provider review before acting.

Review BPC-157

What You'll Learn

  • GHK-Cu human trial data is sparse; most evidence comes from cell culture and animal studies, with no large RCTs confirming skin or hair benefits at any specific timeline.
  • NAD precursor supplementation has been shown to raise blood NAD levels in humans (Yoshino et al., 2021, Science), but cognitive and fatigue endpoints like 'afternoon crash' have not been rigorously tested in clinical settings.
  • The four-week GHK-Cu result timeline circulating online is community consensus, not a figure drawn from published clinical research.
  • Combining multiple peptides without medical supervision carries unknown interaction risks; no human safety data exists for most common peptide stacks.
  • Both GHK-Cu and NAD supplementation are available through compounding pharmacies but are not FDA-approved for skin, hair, or cognitive indications.
  • Open-label self-experimentation makes placebo effects nearly impossible to rule out, which matters when evaluating subjective outcomes like energy and mental clarity.
  • Anyone considering peptide therapy should consult a licensed clinician who can monitor labs, assess quality of compounded products, and adjust protocols based on individual response.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @katgosik actually say?

She described starting GHK-Cu two weeks ago and NAD supplementation three months prior. Her stated reason for NAD: "mental brain function and not having that afternoon crash." For GHK-Cu, she's waiting on results, noting "I think it takes about four weeks to really show in your skin and your hair." She asked her audience what else she should stack.

To be fair, she's not making dramatic medical claims here. She framed both compounds as personal experiments and openly admitted she's noticed nothing from GHK-Cu yet. That kind of epistemic humility is rare in the peptide content space. Still, the video casually invites follower-sourced stacking advice, which carries real risk given that peptide interactions aren't well studied in humans.

Does the science back this up?

Partially, depending on the compound. NAD precursors have decent clinical backing for some energy-related outcomes. GHK-Cu is more complicated.

On NAD: the human data is thin but promising. Yoshino et al. (2021, Science) showed nicotinamide riboside improved muscle insulin sensitivity in older adults. Remie et al. (2020, Nature Communications) found NMN supplementation increased NAD levels in blood. However, most studies use oral NMN or NR, not IV NAD, and "afternoon crash" specifically has not been a primary endpoint in any major trial. The mechanism is real; the specific subjective benefit she describes is plausible but not proven.

On GHK-Cu: the evidence base is almost entirely preclinical. Pickart et al. published extensively on GHK-Cu's role in wound healing and collagen synthesis in cell and animal models, but randomized controlled trials in humans are sparse. A 2015 review by Pickart and Margolina (Journal of Aging Research) summarized tissue repair effects without providing human trial data. Her four-week timeline for skin changes is not drawn from clinical literature; it appears to be community consensus, not science.

What did they get wrong (or right)?

She got a few things right. Acknowledging NAD is not a peptide shows she's done at least some homework. Saying she hasn't noticed GHK-Cu results yet and expecting a longer timeline is more honest than most creators who claim results within days.

Where she's on shakier ground: the four-week skin and hair claim for GHK-Cu has no specific clinical backing. There's no published human trial establishing a four-week onset for visible skin changes from GHK-Cu supplementation. That timeline appears to come from anecdote and forum consensus, not data.

The bigger concern is the open call for stacking recommendations from followers. GHK-Cu combined with other peptides like BPC-157 or TB-500 has zero human safety data as a combination. Crowdsourcing your peptide stack from TikTok comments is not a substitute for clinical oversight, and framing it as casual curiosity doesn't reduce the risk.

What should you actually know?

GHK-Cu is a naturally occurring copper-binding peptide. Its cell-culture and animal data on collagen, wound healing, and inflammation are genuinely interesting. But interesting preclinical data has failed to translate to humans more times than it has succeeded. Until there are well-designed human trials, any specific claim about what it does to your skin or hair in a defined timeframe is speculation.

NAD supplementation has more human evidence behind it, though mostly for metabolic and not cognitive endpoints. If someone reports feeling more alert and less fatigued after three months, that's hard to dismiss entirely. But placebo effects in open-label self-experimentation are substantial, and "afternoon crash" is not a validated clinical outcome.

Both compounds are available through compounding pharmacies and telehealth platforms. Neither is FDA-approved for the uses described. That doesn't make them dangerous by default, but it does mean quality control, dosing standards, and safety monitoring vary widely. Anyone considering these should be working with a licensed clinician, not a comment section.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

kathryn gosik 🫧🤍 · TikTok creator

18.8K views on this video

BPC-157 healing claims on TikTok: what the science shows

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about ghk-cu human trial data?

GHK-Cu human trial data is sparse; most evidence comes from cell culture and animal studies, with no large RCTs confirming skin or hair benefits at any specific timeline.

What does the video say about nad precursor supplementation has been shown to raise blood nad?

NAD precursor supplementation has been shown to raise blood NAD levels in humans (Yoshino et al., 2021, Science), but cognitive and fatigue endpoints like 'afternoon crash' have not been rigorously tested in clinical settings.

What does the video say about the four-week ghk-cu result timeline circulating online?

The four-week GHK-Cu result timeline circulating online is community consensus, not a figure drawn from published clinical research.

What does the video say about combining multiple peptides without medical supervision carries unknown interaction risks;?

Combining multiple peptides without medical supervision carries unknown interaction risks; no human safety data exists for most common peptide stacks.

What does the video say about both ghk-cu?

Both GHK-Cu and NAD supplementation are available through compounding pharmacies but are not FDA-approved for skin, hair, or cognitive indications.

What does the video say about open-label self-experimentation makes placebo effects nearly impossible to rule out,?

Open-label self-experimentation makes placebo effects nearly impossible to rule out, which matters when evaluating subjective outcomes like energy and mental clarity.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by kathryn gosik 🫧🤍, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.